SB-253514 and analogues; novel inhibitors of lipoprotein associated phospholipase A2 produced by Pseudomonas fluorescens DSM 11579. III. Biotransformation using naringinase.
Thirkettle
J
J
SmithKline Beecham Pharmaceuticals, Worthing, West Sussex, UK.
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D000284:Administration, Oral; D000818:Animals; D001671:Biochemistry / Q000379:methods; D001711:Biotransformation; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006026:Glycoside Hydrolases / Q000378:metabolism*; D006031:Glycosylation; D009097:Multienzyme Complexes / Q000378:metabolism*; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D054467:Phospholipases A2; D011551:Pseudomonas fluorescens / Q000378:metabolism; D011714:Pyrans / Q000378:metabolism*; D011817:Rabbits; D013329:Structure-Activity Relationship; D001617:beta-Glucosidase / Q000378:metabolism*
D019086:Bridged Bicyclo Compounds, Heterocyclic; D004791:Enzyme Inhibitors; D009097:Multienzyme Complexes; D011714:Pyrans; C414127:SB 253514; D010741:Phospholipases A; D054467:Phospholipases A2; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D006026:Glycoside Hydrolases; C039827:naringinase; D001617:beta-Glucosidase